R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

R-CEOP Therapy - 21 days, 2026, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6614/510_R-CEOP.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
HSE (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine